Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 16/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 5/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cloprostenol SCHEMBL13399778 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL15390430 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL14913508 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL29407616 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL123596 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL17200671 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL14913507 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL15669946 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL3364442 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB | |
| Cloprostenol SCHEMBL3364445 | 1.00 | PTGFR (1.00) | PTGFRPTGER3TBXA2RPTGER1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358799-A1 | METHODS AND COMPOSITIONS FOR REPRODUCTIVE MANAGEMENT OF SHEEP AND GOATS | REPROLOGIX (US) | 2024-10-31 | — | — | US | claimed |
| WO-2023027950-A1 | METHODS FOR REPRODUCTIVE MANAGEMENT OF SHEEP AND GOATS | REPROLOGIX (US) | 2023-03-02 | — | — | WO | claimed |
| US-20220088000-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2022-03-24 | — | — | US | claimed |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| EP-3852608-A1 | COMPOSITIONS AND METHODS FOR GLAUCOMA | Aufbau Medical Innovations Limited (IE) | 2021-07-28 | — | — | EP | claimed |
| EP-3461484-B9 | DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2021-06-09 | — | — | EP | claimed |
| EP-3810184-A2 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | University of Rochester (US) | 2021-04-28 | — | — | EP | claimed |
| EP-3461484-B1 | DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2020-11-18 | — | — | EP | claimed |
| US-20200276179-A1 | Combination Therapy | ALCON INC. (CH) | 2020-09-03 | — | — | US | claimed |
| EP-2454227-B1 | SYNTHESIS OF PROSTANOIDS | PATHEON API SERVICES INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-5480900-A | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma | ALCON LABORATORIES, INC. (US) | 1996-01-02 | — | — | US | claimed |
| EP-0664707-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA. | ALCON LAB INC (US) | 1995-08-02 | — | — | EP | claimed |
| EP-0639563-A2 | Use of cloprostenol, fluprostenol and their analogues for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension | ALCON LABORATORIES, INC. (US) | 1995-02-22 | — | — | EP | claimed |
| US-5369128-A | Administering a prostaglandin and a peripheral A2 adrenergic agonist | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1994-11-29 | — | — | US | claimed |
| EP-0603800-A1 | Prostaglandin combinations in glaucoma therapy | ALCON LABORATORIES, INC. (US) | 1994-06-29 | — | — | EP | claimed |
| WO-1994008585-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1994-04-28 | — | — | WO | claimed |
| EP-0362686-B1 | METHOD FOR PREPARING THE (+)-ISOMER OF CLOPROSTENOL | SPOLANA a.s. (CZ) | 1993-03-24 | — | — | EP | claimed |
| EP-0362686-A2 | Method for preparing the (+)-isomer of cloprostenol | SPOLANA a.s. (CZ) | 1990-04-11 | — | — | EP | claimed |
| EP-0295619-A2 | Cloprostenol for the control of ovarian functions in farm animals | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1988-12-21 | — | — | EP | claimed |
| US-4686103-A | Method of managing cattle breeding herds | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1987-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088000-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | PTGFR 12/4885PTGER3 11/4885TBXA2R 24/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | PTGFR 1732/4885PTGER3 760/4885TBXA2R 1641/4885 |
| US-20200276179-A1 | Combination Therapy | PTGS1, PTGS2, PTGIS | PTGFR 12/4885PTGER3 11/4885TBXA2R 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.